- The shares of Vertex Pharmaceuticals (VRTX) recently received a $340 price target. These are the details.
The shares of Vertex Pharmaceuticals (VRTX) recently received a $340 price target.
Price target: Increased from $320 to $340
Analyst firm: Argus
Argus analysts adjusted the rating while noting that the company continues to benefit from high sales of Trikafta, its pipeline progress, and partnerships with other organizations. And Argus analysts pointed out that while Vertex is now able to treat most of the 83,000 cystic fibrosis patients in North America, Europe, and Australia, the company management believes that it could treat up to 90% of all people with CF if it receives approval for expanded indications.